Boston Scientific (BSX) Smashed as Sales Miss, Guidance Looks Weak
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $44.70 +2.24%
EPS Growth %: +5.3%
Financial Fact:
Income (loss) before income taxes: 257M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +5.3%
Financial Fact:
Income (loss) before income taxes: 257M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Shares of Boston Scientific (NYSE: BSX) are getting absolutely slammed today amid disappointing Q3 results and a soft Q4 outlook. The stock is currently down 16.4% to $8.50. With about 1.51 billion shares outstanding, Boston Scientific has lost more than $2.5 billion in market cap today.
The supplier of medical equipment reported quarterly adj-EPS of $0.19, topping the Street's estimate by about 5 cents, but missed on the sales figure: $2.02 billion, versus the consensus of $2.04 billion.
As for guidance, Boston Scientific said it sees Q4 non-GAAP EPS of $0.17-$0.21 on sales of $2.025-$2.125 billion. The Street was looking for Q4 EPS and sales of $0.17. and $2.10 billion, respectively.
The supplier of medical equipment reported quarterly adj-EPS of $0.19, topping the Street's estimate by about 5 cents, but missed on the sales figure: $2.02 billion, versus the consensus of $2.04 billion.
As for guidance, Boston Scientific said it sees Q4 non-GAAP EPS of $0.17-$0.21 on sales of $2.025-$2.125 billion. The Street was looking for Q4 EPS and sales of $0.17. and $2.10 billion, respectively.
You May Also Be Interested In
- Citi cuts Boston Scientific rating to neutral, lowers price target
- TD Cowen Boston Scientific (BSX): 'We Maintain Our Constructive 2027-Based View'
- Boston Scientific (BSX) PT Lowered to $60 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Earnings, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
